Lucid Diagnostics (NASDAQ:LUCD) Stock Keeps Buy Rating at BTIG Research

Lucid Diagnostics (NASDAQ:LUCD)‘s stock had its “buy” rating restated by analysts at BTIG Research in a research note issued to investors on Thursday, Benzinga reports.

A number of other research analysts also recently issued reports on the company. Weiss Ratings downgraded Lucid Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 18th. Needham & Company LLC reissued a “buy” rating on shares of Lucid Diagnostics in a research report on Thursday, October 1st. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Lucid Diagnostics currently has a consensus rating of “Moderate Buy” and an average price target of $4.19.

Lucid Diagnostics Trading Up 9.2%

LUCD stock opened at $0.42 on Thursday. The stock has a 50-day moving average price of $0.61 and a two-hundred day moving average price of $0.99. The stock has a market cap of $84.61 million, a PE ratio of -0.89 and a beta of 1.19. Lucid Diagnostics has a 1 year low of $0.30 and a 1 year high of $1.63.

Lucid Diagnostics (NASDAQ:LUCD) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). The firm had revenue of $1.20 million during the quarter, compared to analyst estimates of $1.63 million. On average, analysts forecast that Lucid Diagnostics will post -0.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of LUCD. Alyeska Investment Group L.P. bought a new position in Lucid Diagnostics in the second quarter valued at approximately $9,477,000. BlackRock Inc. acquired a new position in shares of Lucid Diagnostics during the 2nd quarter worth approximately $8,959,000. Two Seas Capital LP bought a new stake in shares of Lucid Diagnostics during the 2nd quarter worth approximately $6,420,000. Sunbelt Securities Inc. raised its stake in shares of Lucid Diagnostics by 134.4% during the 1st quarter. Sunbelt Securities Inc. now owns 900,013 shares of the company’s stock worth $1,035,000 after purchasing an additional 516,014 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of Lucid Diagnostics during the 2nd quarter worth approximately $323,000. 74.01% of the stock is owned by institutional investors and hedge funds.

About Lucid Diagnostics

Lucid Diagnostics is a U.S.-based medical diagnostics company focused on identifying esophageal precancer and cancer. Its primary offering is EsoGuard, a DNA-based test designed to detect cellular changes associated with Barrett’s esophagus, a condition that can increase the risk of esophageal cancer. The test is designed to work with EsoCheck, a swallowable balloon device that collects cells from the esophagus for analysis. Together, the products are intended to provide a less invasive approach to evaluating patients for esophageal disease than traditional endoscopic procedures.